Adavosertib is a tyrosine kinase WEE1 inhibitor used to improve the outcome in triple-negative breast cancer [56], vinorelbine is an agent to treat NSCLC and breast cancer [57], and capivasertib is AKT inhibitor used in the treatment of breast cancer [58]. Here, AKT1 is linked to breast carcinoma.